Zymeworks (ZYME) Tops Q4 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
February 24, 2022 4:15 PM ESTEnrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting. Financial position strengthened and cash runway extended following successful completion of equity offering in January. Announced Chris Astle, PhD as new Chief Financial Officer, with Neil Klompas continuing as Chief Operating Officer. Expected to exceed the previously announced workforce reduction of at least 25% by March 1, 2022, ahead of... More
